Antineoplastic property of Ashwagandha for Paclitaxel concomitant, can induce p53-mediated apoptosis: In vitro search for anti-proliferative phytogent
Cellular and Molecular Therapeutics Laboratory, Venkatesh Natural Extract Pvt. Ltd., Chhindwara, Madhya Pradesh, India.
Research Article
GSC Biological and Pharmaceutical Sciences, 2020, 13(01), 045-053.
Article DOI: 10.30574/gscbps.2020.13.1.0317
Publication history:
Received on 28 September 2020; revised on 05 October 2020; accepted on 08 October 2020
Abstract:
Ashwagandha (Withania somnifera L. Dunal) is an important and traditional medicinal herb found in India. It has been reported that, Ashwagandha has potential anti-proliferative as well as chemo-accelerative activity. The goal of this study was to investigate the most probable reason behind Ashwagandha’s anti-proliferative and chemo-accelerative activity. In addition, chromatographically isolate and chemically characterize some new compound which have antineoplastic property and find the mode of action of it. In vitro assays (MTT and Western blot) for anti-tumorigenic potentiality of the isolated drug were carried out on HT-29, KB and HeLa cell lines. In this experimental study, purification and chemical characterization (by UV, FT-IR, HPLC, LC-MS, 1H-NMR) of an anti-cancer drug has been found as Paclitaxel. MTT-assay shows an average IC50 value of the isolated Paclitaxel is 10 nM. Western blot data reveals there may be ROS-associated p53-MDM2-related cell proliferation and apoptosis by the drug’s in vitro effect.
Keywords:
Paclitaxel; Ashwagandha; 1H-NMR; MTT assay; Western blot
Full text article in PDF:
Copyright information:
Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
